(Reuters) -The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to treat a rare genetic ...
3d
Zacks.com on MSNSLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome DrugSoleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating ...
Vykat XR is specifically indicated to address hyperphagia, or the abnormally strong sensation of hunger, which often leads to ...
The syndrome's symptoms appear immediately, with infants born with low muscle tone ... Anthony Holland, president of the International Prader-Willi Syndrome Organisation said the IPWSO will ...
extended-release tablets for treating hyperphagia in adults and children aged four years and older with Prader-Willi syndrome (PWS). The company expects to launch the drug in the United States in ...
Soleno Therapeutics stock has surged over 1,500% since September 2023, driven by the progress and today's FDA approval of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results